8.645
Cullinan Therapeutics Inc stock is traded at $8.645, with a volume of 594.56K.
It is down -0.40% in the last 24 hours and up +9.43% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$8.68
Open:
$8.57
24h Volume:
594.56K
Relative Volume:
1.32
Market Cap:
$510.23M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.3428
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+10.69%
1M Performance:
+9.43%
6M Performance:
-35.72%
1Y Performance:
-62.07%
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CGEM
Cullinan Therapeutics Inc
|
8.645 | 460.90M | 0 | -153.16M | -134.48M | -3.69 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-24-24 | Initiated | UBS | Buy |
May-01-24 | Initiated | Stifel | Buy |
Apr-15-24 | Initiated | William Blair | Outperform |
Feb-15-24 | Initiated | Wedbush | Outperform |
Jun-15-23 | Initiated | TD Cowen | Outperform |
Nov-21-22 | Initiated | BTIG Research | Buy |
Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Feb-02-21 | Initiated | Evercore ISI | Outperform |
Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
Feb-02-21 | Initiated | SVB Leerink | Outperform |
Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology | CGEM Stock News - GuruFocus
Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - marketscreener.com
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire
ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference | CGEM Stock News - GuruFocus
Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - The Globe and Mail
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) Reveals Promising Phase 2b Results - GuruFocus
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology - GuruFocus
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology Announce Positive Results from REZILIENT1 Trial of Zipalertinib in Advanced Lung Cancer Patients - Nasdaq
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewswire
Northern Trust Corp Raises Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial Markets - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World
Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday - Defense World
Cullinan Therapeutics (CGEM): UBS Lowers Price Target but Mainta - GuruFocus
Cullinan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Lowered to $24.00 at UBS Group - Defense World
UBS Adjusts Price Target on Cullinan Therapeutics to $24 From $30, Maintains Buy Rating - marketscreener.com
Cullinan Therapeutics (CGEM) Price Target Revised by UBS Analyst - GuruFocus
Cullinan Therapeutics Inc Reports Q1 2025 EPS Below Estimates wi - GuruFocus
Cullinan Therapeutics Reports Q1 2025 Financial Results - TipRanks
Cullinan Therapeutics: Q1 Earnings Snapshot - New Haven Register
Dimensional Fund Advisors LP Acquires 295,467 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Cullinan Oncology (CGEM) Projects Financial Runway through 2028 | CGEM Stock News - GuruFocus
Cullinan Therapeutics (CGEM) Advances Autoimmune and Oncology Programs | CGEM Stock News - GuruFocus
Cullinan Therapeutics (CGEM) Advances Autoimmune and Oncology Pr - GuruFocus
MetLife Investment Management LLC Acquires 2,217 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Holdings Lifted by Wells Fargo & Company MN - Defense World
Upcoming US clinical trial will test CLN-978 as Sjögren’s treatment - Sjogren's Syndrome News
Invesco Ltd. Buys 1,395 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Leerink Partnrs Brokers Increase Earnings Estimates for CGEM - Defense World
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know - Yahoo Finance
Cullinan Therapeutics to begin US trial of CLN-978 for treating Sjögren’s disease - Yahoo
Barclays PLC Has $2.99 Million Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Holdings Reduced by Legal & General Group Plc - Defense World
Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease - marketscreener.com
Cullinan Therapeutics (CGEM) Begins Study of CLN-978 for Sjogren - GuruFocus
Cullinan Therapeutics to Initiate Study of CLN-978, a - GlobeNewswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Brokerages - Defense World
SEC Form DEF 14A filed by Cullinan Therapeutics Inc. - Quantisnow
Shareholders Can't Ignore US$502k Of Sales By Cullinan Therapeutics Insiders - simplywall.st
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cullinan Therapeutics Inc Stock (CGEM) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
AHMED NADIM | President and CEO |
Feb 25 '25 |
Sale |
8.53 |
12,529 |
106,872 |
430,621 |
Michaelson Jennifer | Chief Scientific Officer |
Feb 25 '25 |
Sale |
8.53 |
3,756 |
32,039 |
142,004 |
SUMER JACQUELYN L | Chief Legal Officer |
Feb 25 '25 |
Sale |
8.53 |
3,756 |
32,039 |
136,895 |
Michaelson Jennifer | Chief Scientific Officer |
Jan 06 '25 |
Sale |
12.51 |
4,000 |
50,040 |
95,760 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):